Biogen Presents New Data on Antisense Therapy Targeting Tau in Alzheimer’s
- Posted by ISPE Boston
- On November 9, 2023
Biogen has reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in mild Alzheimer’s disease (AD). Antisense therapies are designed to seek out, bind to and destroy a mRNA in a highly specific manner, so that the amount of disease-causing protein is dramatically decreased. The data […]
Read More